Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma receiving ibrutinib for 5 years in the resonate-2 study

HIGHLIGHTS

• who: Jennifer A. Woyach and colleagues from the Ohio State University Comprehensive Cancer Center, Columbus, OH, USA have published the paper: Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for 5 Years in the RESONATE-2 Study, in the Journal: (JOURNAL)
• what: Of the current analysis demonstrate that more than half of patients with previously untreated CLL/SLL were able to receive treatment with single-agent ibrutinib for u22655 years.
• future: Regardless of demographic and disease characteristics at baseline more than half (58%) of the patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.